Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Wilfred E Jaeger. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Wilfred E Jaeger har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:STIM / Neuronetics, Inc. | Director | 138 563 |
US:CNCE / Concert Pharmaceuticals Inc | Director | 0 |
US:NVRO / Nevro Corp. | Director | 9 592 |
US:ACRX / Talphera, Inc. | 10% Owner | 0 |
US:THLD / Threshold Pharmaceuticals, Inc. | Director | 35 000 |
US:LPDX / Liposcience Inc | 10% Owner | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Wilfred E Jaeger. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp STIM / Neuronetics, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i STIM / Neuronetics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-07-02 | STIM | JAEGER WILFRED E | 6 667 | 17,0000 | 6 667 | 17,0000 | 113 339 | 70 | 37.54 | 136 940 | 120,82 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i STIM / Neuronetics, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderköp TLPH / Talphera, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i STIM / Neuronetics, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i STIM / Neuronetics, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Wilfred E Jaeger som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 36 364 | 138 563 | 35,58 | ||||
2023-03-06 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
D - Sale to Issuer | −16 400 | 0 | −100,00 | ||||
2023-03-06 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
U - Other | −5 125 | 0 | −100,00 | ||||
2022-06-13 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 16 400 | 21 525 | 320,00 | ||||
2022-05-31 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 38 910 | 102 187 | 61,49 | ||||
2021-06-11 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 250 | 10 250 | |||||
2021-06-11 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 125 | 5 125 | |||||
2021-06-01 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 7 137 | 63 289 | 12,71 | ||||
2020-08-07 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 18 513 | 56 152 | 49,19 | ||||
2020-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2020-05-28 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 20 000 | 37 639 | 113,39 | ||||
2020-05-26 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 376 | 9 592 | 16,75 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 2 085 | 3 106 | 204,21 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 2 085 | 3 106 | 204,21 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 714 | 25 341 | 2,90 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 16 302 | 25 341 | 180,35 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 1 021 | 3 106 | 48,97 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 1 021 | 3 106 | 48,97 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 349 | 25 341 | 1,40 | ||||
2020-02-14 |
|
5 | NVRO |
NEVRO CORP
Common Stock |
J - Other | 7 976 | 25 341 | 45,93 | ||||
2020-01-06 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 3 062 | 17 639 | 21,01 | 4,49 | 13 748 | 79 199 | |
2019-10-03 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 1 957 | 14 577 | 15,51 | 8,30 | 16 243 | 120 989 | |
2019-07-02 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 1 298 | 12 620 | 11,46 | 12,51 | 16 238 | 157 876 | |
2019-06-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (Right to Buy) |
A - Award | 10 000 | 10 000 | |||||
2019-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Stock Option (right to buy) |
A - Award | 7 347 | 7 347 | |||||
2019-05-30 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 3 723 | 11 322 | 48,99 | ||||
2019-05-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 2 913 | 8 216 | 54,93 | ||||
2019-04-03 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
A - Award | 932 | 7 599 | 13,98 | 14,75 | 13 747 | 112 085 | |
2018-07-05 |
|
4 | STIM |
Neuronetics, Inc.
Stock Option (Right to Buy) |
A - Award | 8 767 | 8 767 | |||||
2018-07-05 |
|
4 | STIM |
Neuronetics, Inc.
Common Stock |
P - Purchase | 6 667 | 6 667 | 17,00 | 113 339 | 113 339 | ||
2018-06-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (Right to Buy) |
A - Award | 10 000 | 10 000 | |||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −126 153 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −5 713 569 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −179 962 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
J - Other | −3 347 357 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 3 785 | 5 303 | 249,34 | ||||
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 461 | 11 042 | −11,69 | 81,42 | −118 958 | 899 064 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −66 125 | 500 109 | −11,68 | 81,42 | −5 384 043 | 40 719 975 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 098 | 12 503 | −8,07 | 80,38 | −88 258 | 1 005 000 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −49 742 | 566 234 | −8,08 | 80,38 | −3 998 297 | 45 514 285 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −910 | 13 601 | −6,27 | 80,19 | −72 969 | 1 090 610 | |
2018-03-07 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −41 206 | 615 976 | −6,27 | 80,19 | −3 304 144 | 49 392 652 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −216 | 14 511 | −1,47 | 80,48 | −17 385 | 1 167 908 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −9 784 | 657 182 | −1,47 | 80,48 | −787 458 | 52 892 833 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −151 | 14 727 | −1,01 | 81,36 | −12 286 | 1 198 226 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 832 | 666 966 | −1,01 | 81,36 | −555 869 | 54 266 021 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −173 | 14 878 | −1,15 | 83,09 | −14 375 | 1 236 276 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 844 | 673 798 | −1,15 | 83,09 | −651 791 | 55 988 706 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −286 | 15 051 | −1,86 | 83,20 | −23 795 | 1 252 212 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −12 972 | 681 642 | −1,87 | 83,20 | −1 079 243 | 56 711 183 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −26 | 15 337 | −0,17 | 84,17 | −2 188 | 1 290 954 | |
2018-03-01 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 174 | 694 614 | −0,17 | 84,17 | −98 819 | 58 467 397 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −286 | 20 764 | −1,36 | 90,31 | −25 829 | 1 875 201 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −12 935 | 940 387 | −1,36 | 90,31 | −1 168 162 | 84 926 538 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −70 | 21 050 | −0,33 | 89,72 | −6 280 | 1 888 503 | |
2017-09-18 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 176 | 953 322 | −0,33 | 89,72 | −284 935 | 85 527 379 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −158 | 21 120 | −0,74 | 87,00 | −13 746 | 1 837 440 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 156 | 956 498 | −0,74 | 87,00 | −622 572 | 83 215 326 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −112 | 21 278 | −0,52 | 87,01 | −9 745 | 1 851 433 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −5 094 | 963 654 | −0,53 | 87,01 | −443 237 | 83 849 076 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −432 | 21 390 | −1,98 | 86,48 | −37 360 | 1 849 820 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −19 568 | 968 748 | −1,98 | 86,48 | −1 692 252 | 83 777 908 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −432 | 21 822 | −1,94 | 85,17 | −36 795 | 1 858 650 | |
2017-08-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −19 568 | 988 316 | −1,94 | 85,17 | −1 666 669 | 84 178 036 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −540 | 22 254 | −2,37 | 84,44 | −45 600 | 1 879 228 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 460 | 1 007 884 | −2,37 | 84,44 | −2 065 512 | 85 110 260 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −331 | 22 794 | −1,43 | 84,02 | −27 810 | 1 915 125 | |
2017-08-21 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −15 012 | 1 032 344 | −1,43 | 84,02 | −1 261 290 | 86 736 304 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −236 | 23 125 | −1,01 | 84,04 | −19 834 | 1 943 462 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −10 701 | 1 047 356 | −1,01 | 84,04 | −899 329 | 88 021 474 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −299 | 23 361 | −1,26 | 82,75 | −24 743 | 1 933 155 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −13 501 | 1 058 057 | −1,26 | 82,75 | −1 117 227 | 87 555 698 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −641 | 23 660 | −2,64 | 82,54 | −52 905 | 1 952 797 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 024 | 1 071 558 | −2,64 | 82,54 | −2 395 519 | 88 441 897 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −546 | 24 301 | −2,20 | 82,40 | −44 991 | 2 002 407 | |
2017-08-16 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 709 | 1 100 582 | −2,20 | 82,40 | −2 036 027 | 90 688 177 | |
2017-06-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 545 | 3 545 | |||||
2017-05-30 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
A - Award | 1 518 | 1 518 | |||||
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −16 | 24 847 | −0,06 | 95,00 | −1 520 | 2 360 465 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −703 | 1 125 291 | −0,06 | 95,00 | −66 785 | 106 902 645 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 | 24 863 | −0,02 | 95,00 | −570 | 2 361 985 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −294 | 1 125 994 | −0,03 | 95,00 | −27 930 | 106 969 430 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −928 | 24 869 | −3,60 | 95,03 | −88 191 | 2 363 383 | |
2017-03-03 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −42 033 | 1 126 288 | −3,60 | 95,03 | −3 994 535 | 107 034 865 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −79 | 25 797 | −0,31 | 99,89 | −7 891 | 2 576 847 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −137 | 25 876 | −0,53 | 98,58 | −13 505 | 2 550 727 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 567 | 1 168 321 | −0,30 | 99,89 | −356 305 | 116 702 884 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −6 217 | 1 171 888 | −0,53 | 98,58 | −612 841 | 115 518 860 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −370 | 26 013 | −1,40 | 98,30 | −36 372 | 2 557 161 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 034 | 26 383 | −3,77 | 97,86 | −101 192 | 2 581 964 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −16 753 | 1 178 105 | −1,40 | 98,30 | −1 646 874 | 115 811 491 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −46 843 | 1 194 858 | −3,77 | 97,86 | −4 584 276 | 116 934 420 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −50 | 27 417 | −0,18 | 98,14 | −4 907 | 2 690 608 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 459 | 27 467 | −5,04 | 97,53 | −142 300 | 2 678 922 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −216 | 28 926 | −0,74 | 96,88 | −20 926 | 2 802 391 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 250 | 1 241 701 | −0,18 | 98,14 | −220 807 | 121 856 190 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −66 066 | 1 243 951 | −5,04 | 97,53 | −6 443 576 | 121 325 527 | |
2016-08-22 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −9 799 | 1 310 017 | −0,74 | 96,88 | −949 341 | 126 916 281 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −661 | 29 142 | −2,22 | 96,16 | −63 559 | 2 802 161 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 953 | 1 319 816 | −2,22 | 96,16 | −2 880 143 | 126 907 435 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −73 | 29 803 | −0,24 | 97,06 | −7 086 | 2 892 801 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −457 | 29 876 | −1,51 | 96,02 | −43 880 | 2 868 601 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 327 | 1 349 769 | −0,25 | 97,06 | −322 932 | 131 014 113 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −20 689 | 1 353 096 | −1,51 | 96,02 | −1 986 494 | 129 920 083 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −121 | 30 333 | −0,40 | 98,66 | −11 938 | 2 992 608 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 039 | 30 454 | −6,28 | 97,90 | −199 617 | 2 981 437 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −5 487 | 1 373 785 | −0,40 | 98,66 | −541 339 | 135 535 567 | |
2016-08-17 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −92 353 | 1 379 272 | −6,28 | 97,90 | −9 041 331 | 135 030 315 | |
2016-06-28 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 35 000 | 35 000 | |||||
2016-06-10 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2016-05-20 |
|
4 | NVRO |
NEVRO CORP
Stock Option (Right to Buy) |
A - Award | 3 240 | 3 240 | |||||
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −29 | 32 493 | −0,09 | 64,02 | −1 857 | 2 080 182 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 314 | 1 471 625 | −0,09 | 64,02 | −84 121 | 94 212 550 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −78 | 32 522 | −0,24 | 65,54 | −5 112 | 2 131 365 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −174 | 32 600 | −0,53 | 64,01 | −11 137 | 2 086 628 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −3 522 | 1 472 939 | −0,24 | 65,54 | −230 818 | 96 530 678 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −7 866 | 1 476 461 | −0,53 | 64,01 | −503 479 | 94 503 839 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −91 | 32 774 | −0,28 | 65,47 | −5 957 | 2 145 609 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 069 | 32 865 | −5,92 | 64,68 | −133 813 | 2 125 544 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −4 140 | 1 484 327 | −0,28 | 65,47 | −271 033 | 97 174 139 | |
2016-05-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −93 700 | 1 488 467 | −5,92 | 64,68 | −6 060 048 | 96 266 603 | |
2016-03-01 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
J - Other | −27 500 | 52 500 | −34,38 | ||||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −113 | 0 | −100,00 | 19,57 | −2 211 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 066 | 0 | −100,00 | 19,57 | −99 119 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −265 | 0 | −100,00 | 19,57 | −5 185 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −4 916 | 0 | −100,00 | 19,57 | −96 184 | ||
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −589 | 113 | −83,90 | 20,10 | −11 841 | 2 272 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −26 697 | 5 066 | −84,05 | 20,10 | −536 719 | 101 847 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 392 | 265 | −84,01 | 20,10 | −27 985 | 5 328 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −25 894 | 4 916 | −84,04 | 20,10 | −520 576 | 98 832 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −42 | 702 | −5,65 | 20,09 | −844 | 14 102 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 919 | 31 763 | −5,70 | 20,09 | −38 549 | 638 058 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −100 | 1 657 | −5,69 | 20,09 | −2 009 | 33 286 | |
2015-12-16 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 861 | 30 810 | −5,70 | 20,09 | −37 384 | 618 914 | |
2015-11-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −540 | 34 934 | −1,52 | 53,48 | −28 880 | 1 868 312 | |
2015-11-24 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −24 460 | 1 582 167 | −1,52 | 53,48 | −1 308 150 | 84 616 190 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −696 | 35 474 | −1,92 | 53,16 | −36 999 | 1 885 773 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −2 040 | 36 170 | −5,34 | 52,08 | −106 237 | 1 883 618 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −31 496 | 1 606 627 | −1,92 | 53,16 | −1 674 305 | 85 407 167 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −92 400 | 1 638 123 | −5,34 | 52,08 | −4 811 896 | 85 308 204 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −1 045 | 38 210 | −2,66 | 51,94 | −54 276 | 1 984 589 | |
2015-11-19 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −47 323 | 1 730 523 | −2,66 | 51,94 | −2 457 909 | 89 881 634 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 296 | 744 | −63,53 | 18,22 | −23 613 | 13 556 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −58 704 | 33 682 | −63,54 | 18,22 | −1 069 587 | 613 686 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −3 062 | 1 757 | −63,54 | 18,22 | −55 790 | 32 013 | |
2015-09-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −56 938 | 32 671 | −63,54 | 18,22 | −1 037 410 | 595 266 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 805 | 2 040 | −76,94 | 15,70 | −106 838 | 32 028 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −308 195 | 92 386 | −76,94 | 15,70 | −4 838 662 | 1 450 460 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −16 071 | 4 819 | −76,93 | 15,70 | −252 315 | 75 658 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −298 929 | 89 609 | −76,94 | 15,70 | −4 693 185 | 1 406 861 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 404 | 8 845 | −13,70 | 16,32 | −22 913 | 144 350 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −63 596 | 400 581 | −13,70 | 16,32 | −1 037 887 | 6 537 482 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −3 316 | 20 890 | −13,70 | 16,32 | −54 117 | 340 925 | |
2015-08-18 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −61 684 | 388 538 | −13,70 | 16,32 | −1 006 683 | 6 340 940 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −996 | 10 249 | −8,86 | 16,75 | −16 683 | 171 671 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −45 112 | 464 177 | −8,86 | 16,75 | −755 626 | 7 774 965 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 352 | 24 206 | −8,86 | 16,75 | −39 396 | 405 450 | |
2015-08-17 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −43 755 | 450 222 | −8,86 | 16,75 | −732 896 | 7 541 218 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 056 | 11 245 | −8,58 | 14,49 | −15 301 | 162 937 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −47 837 | 509 289 | −8,59 | 14,49 | −693 144 | 7 379 445 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 494 | 26 558 | −8,58 | 14,49 | −36 137 | 384 817 | |
2015-08-14 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −46 398 | 493 977 | −8,59 | 14,49 | −672 293 | 7 157 579 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 056 | 11 245 | −8,58 | 17,49 | −18 469 | 196 672 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −47 837 | 509 289 | −8,59 | 17,49 | −836 655 | 8 907 312 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −2 494 | 26 558 | −8,58 | 17,49 | −43 619 | 464 491 | |
2015-08-14 |
|
4/A | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −46 398 | 493 977 | −8,59 | 17,49 | −811 487 | 8 639 510 | |
2015-07-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2015-06-15 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2015-06-08 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −8 500 | 39 255 | −17,80 | 47,94 | −407 490 | 1 881 885 | |
2015-06-08 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
S - Sale | −384 968 | 1 777 846 | −17,80 | 47,94 | −18 455 366 | 85 229 937 | |
2015-06-01 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 4 182 | 4 182 | |||||
2015-02-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock Warrant (Right to Buy) |
P - Purchase | 25 000 | 25 000 | |||||
2015-02-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 25 000 | 80 000 | 45,45 | 3,74 | 93 625 | 299 600 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −5 400 | 12 301 | −30,51 | 12,29 | −66 366 | 151 179 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −244 600 | 557 126 | −30,51 | 12,29 | −3 006 134 | 6 847 079 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −12 755 | 29 052 | −30,51 | 12,29 | −156 759 | 357 049 | |
2014-11-20 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −237 245 | 540 375 | −30,51 | 12,29 | −2 915 741 | 6 641 209 | |
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series C Preferred Stock |
C - Conversion | −4 506 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series B Preferred Stock |
C - Conversion | −15 069 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series A Preferred Stock |
C - Conversion | −28 090 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series C Preferred Stock |
C - Conversion | −204 076 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series B Preferred Stock |
C - Conversion | −682 475 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Series A Preferred Stock |
C - Conversion | −1 272 187 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 4 506 | 47 755 | 10,42 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 15 069 | 43 249 | 53,47 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 28 090 | 28 180 | 31 211,11 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 204 076 | 2 162 814 | 10,42 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 682 475 | 1 958 738 | 53,47 | ||||
2014-11-12 |
|
4 | NVRO |
NEVRO CORP
Common Stock |
C - Conversion | 1 272 187 | 1 276 263 | 31 211,65 | ||||
2014-11-07 |
|
4 | NVRO |
NEVRO CORP
Stock Option (right to buy) |
A - Award | 8 477 | 8 477 | |||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
8 242 | ||||||||
2014-11-05 | 3 | NVRO |
NEVRO CORP
Common Stock |
4 256 | ||||||||
2014-05-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −391 359 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −1 956 794 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −1 467 595 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −8 641 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −43 206 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −32 405 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 101 264 | 801 726 | 14,46 | 14,00 | 1 417 696 | 11 224 164 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 2 236 | 17 701 | 14,46 | 14,00 | 31 304 | 247 814 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 69 267 | 700 462 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 346 335 | 631 195 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 259 751 | 284 860 | 1 034,49 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 1 529 | 15 465 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 7 647 | 13 936 | 121,59 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 5 735 | 6 289 | 1 035,20 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −379 592 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −1 897 959 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −1 423 469 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | −20 408 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | −102 041 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | −76 531 | 0 | −100,00 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 98 219 | 777 620 | 14,46 | 14,00 | 1 375 066 | 10 886 680 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 5 281 | 41 807 | 14,46 | 14,00 | 73 934 | 585 298 | |
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 67 184 | 679 401 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 335 922 | 612 217 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 251 941 | 276 295 | 1 034,50 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 3 612 | 36 526 | 10,97 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 18 060 | 32 914 | 121,58 | ||||
2014-02-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 13 545 | 14 854 | 1 034,76 | ||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 217 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 772 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
26 972 | ||||||||
2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
50 017 | ||||||||
2014-01-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 907 | 0 | −100,00 | 4,86 | −23 832 | ||
2014-01-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −91 449 | 0 | −100,00 | 4,86 | −444 140 | ||
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 204 | 4 907 | −67,53 | 4,86 | −49 561 | 23 833 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −189 796 | 91 449 | −67,48 | 4,86 | −921 839 | 444 168 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 000 | 15 111 | −24,86 | 4,87 | −24 330 | 73 530 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −93 000 | 281 245 | −24,85 | 4,87 | −452 538 | 1 368 538 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 477 | 20 111 | −24,36 | 4,90 | −31 705 | 98 443 | |
2014-01-15 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −120 479 | 374 245 | −24,35 | 4,90 | −589 745 | 1 831 929 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −14 286 | 26 588 | −34,95 | 4,87 | −69 597 | 129 529 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −265 714 | 494 724 | −34,94 | 4,87 | −1 294 479 | 2 410 147 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −10 204 | 40 874 | −19,98 | 4,87 | −49 668 | 198 954 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −189 796 | 760 438 | −19,97 | 4,87 | −923 832 | 3 701 432 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −12 444 | 51 078 | −19,59 | 4,90 | −60 957 | 250 206 | |
2014-01-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −231 456 | 950 234 | −19,59 | 4,90 | −1 133 787 | 4 654 721 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 552 | 63 522 | −6,69 | 5,52 | −25 118 | 350 514 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −84 648 | 1 181 690 | −6,68 | 5,52 | −467 088 | 6 520 565 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −11 877 | 68 074 | −14,86 | 5,54 | −65 787 | 377 062 | |
2013-07-16 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −220 923 | 1 266 338 | −14,85 | 5,54 | −1 223 692 | 7 014 246 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 918 | 79 951 | −6,89 | 5,52 | −32 672 | 441 385 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −110 082 | 1 487 261 | −6,89 | 5,52 | −607 730 | 8 210 722 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 163 | 85 869 | −3,55 | 5,50 | −17 400 | 472 374 | |
2013-07-12 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −58 837 | 1 597 343 | −3,55 | 5,50 | −323 668 | 8 787 144 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 897 | 89 032 | −5,21 | 5,48 | −26 836 | 487 895 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −91 070 | 1 656 180 | −5,21 | 5,48 | −499 064 | 9 075 866 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 311 | 93 929 | −6,30 | 5,56 | −35 089 | 522 245 | |
2013-07-08 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −117 389 | 1 747 250 | −6,30 | 5,56 | −652 683 | 9 714 710 | |
2013-06-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −102 | 100 240 | −0,10 | 5,50 | −561 | 551 671 | |
2013-06-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 898 | 1 864 639 | −0,10 | 5,50 | −10 446 | 10 262 041 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 649 | 100 342 | −3,51 | 5,50 | −20 075 | 552 021 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −67 862 | 1 866 537 | −3,51 | 5,50 | −373 336 | 10 268 567 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 715 | 103 991 | −2,54 | 5,53 | −15 006 | 574 758 | |
2013-06-19 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −50 507 | 1 934 399 | −2,54 | 5,53 | −279 152 | 10 691 423 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 735 | 106 706 | −2,50 | 5,50 | −15 043 | 586 915 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −50 865 | 1 984 906 | −2,50 | 5,50 | −279 773 | 10 917 578 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 102 | 109 441 | −4,45 | 5,47 | −27 893 | 598 325 | |
2013-06-11 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −94 898 | 2 035 771 | −4,45 | 5,47 | −518 817 | 11 129 764 | |
2013-05-20 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series F Convertible Preferred Stock |
C - Conversion | −25 261 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series F Convertible Preferred Stock |
C - Conversion | −534 339 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series E Convertible Preferred Stock |
C - Conversion | −41 509 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series E Convertible Preferred Stock |
C - Conversion | −878 030 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock |
C - Conversion | −69 183 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Series D-1 Convertible Preferred Stock |
C - Conversion | −1 463 385 | 0 | −100,00 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
P - Purchase | 9 705 | 83 739 | 13,11 | 9,00 | 87 345 | 753 651 | |
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
P - Purchase | 205 295 | 1 771 347 | 13,11 | 9,00 | 1 847 655 | 15 942 123 | |
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
C - Conversion | 72 646 | 74 034 | 5 233,86 | ||||
2013-01-31 |
|
4 | LPDX |
LIPOSCIENCE INC
Common Stock |
C - Conversion | 1 536 688 | 1 566 052 | 5 233,24 | ||||
2013-01-24 | 3 | LPDX |
LIPOSCIENCE INC
Common Stock |
29 364 | ||||||||
2013-01-24 | 3 | LPDX |
LIPOSCIENCE INC
Common Stock |
1 388 | ||||||||
2012-12-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 52 213 | 139 621 | 59,73 | 3,31 | 172 825 | 462 146 | |
2012-12-11 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 2 364 705 | 6 323 534 | 59,73 | 3,31 | 7 827 174 | 20 930 898 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −12 500 | 20 000 | −38,46 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −12 500 | 20 000 | −38,46 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −10 000 | 45 000 | −18,18 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −10 000 | 45 000 | −18,18 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 55 000 | −4,35 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 55 000 | −4,35 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 57 500 | −4,17 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (right to buy) |
M - Exercise | −2 500 | 60 000 | −4,00 | ||||
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 500 | 55 000 | 29,41 | 1,64 | 20 500 | 90 200 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 500 | 42 500 | 41,67 | 1,62 | 20 250 | 68 850 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 30 000 | 50,00 | 1,95 | 19 500 | 58 500 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 20 000 | 14,29 | 1,30 | 3 250 | 26 000 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 20 000 | 14,29 | 1,30 | 3 250 | 26 000 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 15 000 | 20,00 | 1,30 | 3 250 | 19 500 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 500 | 12 500 | 25,00 | 1,30 | 3 250 | 16 250 | |
2012-09-06 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
M - Exercise | 10 000 | 10 000 | 0,79 | 7 900 | 7 900 | ||
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −14 612 | 114 543 | −11,31 | 7,98 | −116 566 | 913 755 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −271 788 | 2 129 669 | −11,32 | 7,98 | −2 168 162 | 16 989 221 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −25 510 | 129 155 | −16,49 | 8,02 | −204 649 | 1 036 120 | |
2012-08-27 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −474 490 | 2 401 457 | −16,50 | 8,02 | −3 806 501 | 19 265 208 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −2 990 | 154 665 | −1,90 | 7,52 | −22 473 | 1 162 493 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −56 610 | 2 875 947 | −1,93 | 7,52 | −425 492 | 21 616 193 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 531 | 157 655 | −0,96 | 7,50 | −11 482 | 1 182 412 | |
2012-08-23 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −28 469 | 2 932 557 | −0,96 | 7,50 | −213 518 | 21 994 178 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −21 369 | 0 | −100,00 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −20 007 | 21 369 | −48,35 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −397 478 | 0 | −100,00 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | −372 149 | 397 478 | −48,35 | ||||
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 21 369 | 159 186 | 15,51 | 2,05 | 43 806 | 326 331 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 20 007 | 137 817 | 16,98 | 1,86 | 37 213 | 256 340 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 397 478 | 2 961 026 | 15,50 | 2,05 | 814 830 | 6 070 103 | |
2012-08-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
X - Other | 372 149 | 2 563 548 | 16,98 | 1,86 | 692 197 | 4 768 199 | |
2012-07-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 377 | 117 810 | −5,13 | 8,01 | −51 101 | 944 047 | |
2012-07-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −118 623 | 2 191 399 | −5,14 | 8,01 | −950 562 | 17 560 338 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 4 151 | 4 151 | 0,12 | 519 | 519 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 188 020 | 188 020 | 0,12 | 23 502 | 23 502 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 3 268 | 3 268 | 0,12 | 408 | 408 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 60 789 | 60 789 | 0,12 | 7 599 | 7 599 | ||
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4 613 | 87 408 | 5,57 | 3,40 | 15 684 | 297 187 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 208 911 | 3 958 829 | 5,57 | 3,40 | 710 297 | 13 460 019 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3 631 | 199 174 | 1,86 | 3,40 | 12 345 | 677 192 | |
2012-06-06 |
|
4/A | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 67 543 | 3 704 712 | 1,86 | 3,40 | 229 646 | 12 596 021 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 4 151 | 4 151 | 0,12 | 519 | 519 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 188 020 | 188 020 | 0,12 | 23 502 | 23 502 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 3 268 | 3 268 | 0,12 | 408 | 408 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Warrant to purchase Common Stock |
P - Purchase | 60 789 | 60 789 | 0,12 | 7 599 | 7 599 | ||
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4 613 | 87 408 | 5,57 | 3,40 | 15 684 | 297 187 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 208 911 | 3 958 829 | 5,57 | 3,40 | 710 297 | 13 460 019 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 3 631 | 199 174 | 1,86 | 3,40 | 12 345 | 677 192 | |
2012-05-31 |
|
4 | ACRX |
ACELRX PHARMACEUTICALS INC
Common Stock |
P - Purchase | 67 543 | 3 704 712 | 1,86 | 3,40 | 229 646 | 12 596 021 | |
2012-05-21 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2007-05-17 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2006-03-07 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 000 000 | 2 440 202 | −29,07 | 14,50 | −14 500 000 | 35 382 929 | |
2005-02-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 11 939 | 175 491 | 7,30 | 7,00 | 83 573 | 1 228 437 | |
2005-02-10 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 222 059 | 3 264 711 | 7,30 | 7,00 | 1 554 413 | 22 852 977 | |
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | −154 607 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | −2 875 696 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | −114 750 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | −2 135 250 | 0 | −100,00 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 93 877 | 163 552 | 134,74 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1 746 126 | 3 042 652 | 134,68 | ||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 69 675 | 69 675 | |||||
2005-02-03 |
|
4 | THLD |
THRESHOLD PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1 296 526 | 1 296 526 |